Posts belonging to Category Clinical Trials

Study Shows Neuralstem Cells Transplanted Into Brain Significantly Improve Post-Stroke Symptoms in Rats

The researchers concluded that the NSI-566 cells are potent cell donors for transplantation therapy to treat paralysis in stroke patients

BrainStorm and Mass General Sign Definitive Agreement for ALS Clinical Trial

BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Massachusetts General Hospital (MGH) in Boston, MA to conduct a Phase II clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS).

ImStar Selects Lead ALS Drug Candidate for Study by Mid-2014

“We are very excited to announce the selection of IMS-088 as ImStar’s lead ALS compound. As we continue with preclinical development next year, we hope to establish IMS-088 as a safe and effective new drug candidate for ALS,” said Jean-Pierre Julien, ImStar’s chief scientific officer.

Neuraltus’ NP001 Phase 2 Results Highlighted at 24th International Symposium on ALS/MND

According to a post hoc analysis, a greater percentage of patients receiving NP001 experienced a halt in disease progression which reached statistical significance when compared to the combination of concurrent and matched historical (placebo) controls. The high dose of NP001 (2mg/kg) halted progression in 27% of patients compared to 11% of patients on placebo. Further, NP001 was found to be safe and well-tolerated in the study.

Cytokinetics to Present BENEFIT-ALS Trial Insights at International Symposium

Cytokinetics will elaborate on the clinical trial design and include enrollment and baseline demographics data from BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS), which is evaluating tirasemtiv, a novel mechanism skeletal muscle activator, as a potential treatment for patients with amyotrophic lateral sclerosis (ALS).

Acceleration of Clinical Program in ALS Confirms Proof of Efficacy Data Obtained in Animals

AB Science SA, a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces, following the press release from November 4, that the acceleration of the clinical development program in ALS is in line with proof of efficacy experiments conducted in two different models that generated positive results of increased survival.

New ALS Drug Headed for Phase IIa Trial

Researchers at Houston Methodist Neurological Institute and elsewhere will soon begin phase IIa clinical trials of TDI-132, a drug that in animal models has shown promise in reducing the inflammation associated with Amyotrophic Lateral Sclerosis, also known as ALS or Lou Gehrig’s Disease.

Neuraltus Seeks $30 Million for New ALS Phase IIb Drug Trial

Richard Casey, Neuraltus’ newly appointed CEO, said Wednesday at the Biotechnology Industry Organization’s investor forum that a Phase IIb trial of 300 patients with the muscle-wasting disease will start enrolling patients in the first quarter of 2014. The final patient will be dosed in second-quarter 2015, and early data is expected in third-quarter 2015.

First Patient Treated in Phase II of Neuralstem ALS Stem Cell Trial

This Phase II Neuralstem study is designed to determine the safety of the maximum tolerated dose of human spinal cord-derived neural stem cell transplantation for the treatment of amyotrophic lateral sclerosis (ALS).

Neuralstem ALS Trial Data Presented at the American Association of Neurological Surgeons Annual Meeting

“That our cells and method of delivery are safe in ALS patients bodes very well for expanding to other indications. We expect to commence our FDA-approved Phase I trial in chronic spinal cord injury later this year using the same methodology. We want to thank the surgeons at Emory, who developed these techniques, as well as the patients and their families who have taken part in the trial.”